Rhumbline Advisers Myriad Genetics Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Myriad Genetics Inc stock. As of the latest transaction made, Rhumbline Advisers holds 277,358 shares of MYGN stock, worth $4.24 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
277,358
Previous 283,435 2.14%
Holding current value
$4.24 Million
Previous $6.93 Million 9.51%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$23.97 - $28.6 $145,665 - $173,802
-6,077 Reduced 2.14%
277,358 $7.59 Million
Q2 2024

Aug 01, 2024
BUY
$17.98 - $25.47 $121,562 - $172,202
6,761 Added 2.44%
283,435 $6.93 Million
Q1 2024

May 09, 2024
BUY
$17.59 - $23.59 $95,900 - $128,612
5,452 Added 2.01%
276,674 $5.9 Million
Q4 2023

Feb 08, 2024
BUY
$13.91 - $21.32 $26,637 - $40,827
1,915 Added 0.71%
271,222 $5.19 Million
Q3 2023

Nov 09, 2023
BUY
$15.99 - $23.22 $20,994 - $30,487
1,313 Added 0.49%
269,307 $4.32 Million
Q2 2023

Aug 08, 2023
SELL
$17.56 - $23.76 $17,208 - $23,284
-980 Reduced 0.36%
267,994 $6.21 Million
Q1 2023

May 11, 2023
BUY
$15.26 - $23.75 $172,163 - $267,947
11,282 Added 4.38%
268,974 $6.25 Million
Q4 2022

Feb 14, 2023
BUY
$14.51 - $20.99 $160,466 - $232,128
11,059 Added 4.48%
257,692 $3.74 Million
Q3 2022

Nov 10, 2022
BUY
$18.21 - $27.88 $164,436 - $251,756
9,030 Added 3.8%
246,633 $4.71 Million
Q2 2022

Aug 11, 2022
BUY
$16.45 - $25.88 $173,744 - $273,344
10,562 Added 4.65%
237,603 $4.32 Million
Q1 2022

May 12, 2022
SELL
$22.67 - $28.01 $17,818 - $22,015
-786 Reduced 0.34%
227,041 $5.72 Million
Q4 2021

Feb 10, 2022
SELL
$24.13 - $32.63 $58,949 - $79,715
-2,443 Reduced 1.06%
227,827 $6.29 Million
Q3 2021

Nov 12, 2021
SELL
$29.97 - $36.66 $789,170 - $965,331
-26,332 Reduced 10.26%
230,270 $7.44 Million
Q2 2021

Aug 05, 2021
SELL
$25.39 - $32.61 $205,633 - $264,108
-8,099 Reduced 3.06%
256,602 $7.85 Million
Q1 2021

May 06, 2021
SELL
$19.92 - $31.6 $2,191 - $3,476
-110 Reduced 0.04%
264,701 $8.06 Million
Q4 2020

Feb 10, 2021
BUY
$12.16 - $19.77 $351,436 - $571,372
28,901 Added 12.25%
264,811 $5.24 Million
Q3 2020

Nov 12, 2020
SELL
$11.25 - $14.75 $169,605 - $222,371
-15,076 Reduced 6.01%
235,910 $3.08 Million
Q2 2020

Aug 13, 2020
SELL
$10.69 - $16.49 $158,073 - $243,837
-14,787 Reduced 5.56%
250,986 $2.85 Million
Q1 2020

May 06, 2020
BUY
$9.78 - $29.53 $154,934 - $467,814
15,842 Added 6.34%
265,773 $3.8 Million
Q4 2019

Feb 05, 2020
BUY
$20.93 - $35.1 $318,303 - $533,800
15,208 Added 6.48%
249,931 $6.81 Million
Q3 2019

Oct 23, 2019
BUY
$22.08 - $47.08 $302,915 - $645,890
13,719 Added 6.21%
234,723 $6.72 Million
Q2 2019

Aug 14, 2019
BUY
$22.67 - $35.0 $365,327 - $564,025
16,115 Added 7.87%
221,004 $6.14 Million
Q1 2019

May 01, 2019
SELL
$26.93 - $34.7 $58,491 - $75,368
-2,172 Reduced 1.05%
204,889 $6.8 Million
Q4 2018

Jan 31, 2019
BUY
$27.23 - $45.56 $1.23 Million - $2.05 Million
45,070 Added 27.82%
207,061 $6.02 Million
Q3 2018

Nov 07, 2018
SELL
$37.57 - $50.34 $89,341 - $119,708
-2,378 Reduced 1.45%
161,991 $7.45 Million
Q2 2018

Aug 06, 2018
SELL
$27.75 - $40.17 $23,171 - $33,541
-835 Reduced 0.51%
164,369 $6.14 Million
Q1 2018

May 02, 2018
BUY
$28.83 - $41.01 $86,057 - $122,414
2,985 Added 1.84%
165,204 $4.88 Million
Q4 2017

Feb 09, 2018
BUY
$28.45 - $37.14 $706,669 - $922,520
24,839 Added 18.08%
162,219 $5.57 Million
Q3 2017

Nov 06, 2017
BUY
$24.01 - $36.2 $3.3 Million - $4.97 Million
137,380
137,380 $4.97 Million

Others Institutions Holding MYGN

# of Institutions
253
Shares Held
90.9M
Call Options Held
100K
Put Options Held
34K
View Full List

About MYRIAD GENETICS INC

MYGN Quotes by TradingView
  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.23B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email